<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346083</url>
  </required_header>
  <id_info>
    <org_study_id>16-021</org_study_id>
    <nct_id>NCT03346083</nct_id>
  </id_info>
  <brief_title>Study Evaluating PK/PD and Safety of Betrixaban in Pediatric Patients</brief_title>
  <official_title>A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Betrixaban in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portola Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Portola Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics,&#xD;
      Pharmacodynamics, and Safety of Betrixaban in Pediatric Patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Actual">October 8, 2019</completion_date>
  <primary_completion_date type="Actual">October 8, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) - AUC(0-∞)</measure>
    <time_frame>Day 1 - Day 6 (120 hours)</time_frame>
    <description>Total area under the plasma concentration-time curve from 0 to infinity (AUC(0-∞))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) - Cmax</measure>
    <time_frame>Day 1 - Day 6 (120 hours)</time_frame>
    <description>Maximum observed plasma concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK - (AUC(0-last))</measure>
    <time_frame>Day 1 - Day 6</time_frame>
    <description>Area under the concentration-time curve to the last measurable concentration above the quantitation limit (AUC(0-last))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK - (t½)</measure>
    <time_frame>Day 1 - Day 6</time_frame>
    <description>Terminal plasma half-life (t½)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK - (Tmax)</measure>
    <time_frame>Day 1 - Day 6</time_frame>
    <description>Time to maximum observed plasma concentration (Tmax )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK - (CL)</measure>
    <time_frame>Day 1 - Day 6</time_frame>
    <description>Clearance (CL) and volume of distribution (Vd)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic (PD) - Thrombin Level</measure>
    <time_frame>Day 1 - Day 6</time_frame>
    <description>The pharmacodynamic (PD) endpoint is the inhibition of thrombin generation during the first 24 hours post dosing, evaluated by the percent change in thrombin level from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with treatment related Adverse Events (AE)</measure>
    <time_frame>Day 1 - Day 6</time_frame>
    <description>The safety endpoint is the clinical assessment of AEs and other safety measurements (vital signs, ECGs, laboratory tests, etc.)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>VTE Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Bertrixaban/Andexanet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Bertrixaban/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose 80 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betrixaban</intervention_name>
    <description>Factor Xa</description>
    <arm_group_label>Cohort 1 Bertrixaban/Andexanet</arm_group_label>
    <arm_group_label>Cohort 2 Bertrixaban/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pediatric patients in the following age categories: 12 to &lt; 18 years of age, 2 to &lt; 12&#xD;
             years of age, and 28 days to &lt; 2 years of age. Part 1 of the study will enroll only&#xD;
             adolescent patients 12 to &lt; 18 years of age.&#xD;
&#xD;
          2. Patient is a pediatric subject requiring anticoagulant therapy, for example:&#xD;
&#xD;
               1. Has previous thrombosis and completed a course of anti-coagulant therapy, and is&#xD;
                  considered to have a risk for recurrence of VTE, or&#xD;
&#xD;
               2. Has any stable disease with a risk for arterial or venous thrombotic disorder, or&#xD;
&#xD;
               3. Has any functional CVAD (Central Venous Access Device) in the upper or lower&#xD;
                  venous system.&#xD;
&#xD;
          3. Patient has normalized coagulation parameters from recent anticoagulant therapy (INR&#xD;
             or PTT, as appropriate) within 7 days of study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any one of the following exclusion criteria will be excluded from the&#xD;
        study:&#xD;
&#xD;
          1. Patient received any dose of anti-coagulant therapy within 7 days of Day 1.&#xD;
&#xD;
          2. Patient has active bleeding or has a comorbid disorder that places the patient at high&#xD;
             risk for bleeding.&#xD;
&#xD;
          3. Patient has a comorbid disorder that places the patient at risk of death within 90&#xD;
             days of enrollment.&#xD;
&#xD;
          4. Patient has abnormal coagulation tests at baseline.&#xD;
&#xD;
          5. Patient has had recent or planned invasive procedures, including lumbar puncture and&#xD;
             removal of non-peripherally placed central lines during study.&#xD;
&#xD;
          6. Patient has hepatic disease associated with one or more of the following:&#xD;
&#xD;
               -  Transaminase levels ≥ 2.5 × upper limit of normal (ULN) or bilirubin ≥ 1.5 × ULN&#xD;
                  at baseline.&#xD;
&#xD;
               -  Coagulopathy leading to a clinically relevant bleeding risk, or hepatic&#xD;
                  transaminase level of &gt; 2 × upper level of normal (ULN) or total bilirubin &gt; 2 ×&#xD;
                  ULN with direct bilirubin &gt; 20% of the total.&#xD;
&#xD;
               -  Platelet count &lt; 75 × 109/L or hemoglobin &lt; 10.0 mg/dL.&#xD;
&#xD;
               -  Hypertension defined as &gt; 95th percentile for age. Refer to Appendix A.&#xD;
&#xD;
          7. Patient has known congenital or acquired bleeding diathesis.&#xD;
&#xD;
          8. Patient requires concomitant therapy with a strong P-gp inhibitor.&#xD;
&#xD;
          9. Patient has previous history of any non-traumatic bleeding event that was life&#xD;
             threatening or required medical attention.&#xD;
&#xD;
         10. Patient had been administered thrombolytic therapy, or had undergone thrombectomy, or&#xD;
             insertion of a caval filter to treat prior VTE.&#xD;
&#xD;
         11. Patient has known inherited or acquired bleeding diathesis or coagulopathy.&#xD;
&#xD;
         12. Patient has abnormal QTcF interval on baseline ECG.&#xD;
&#xD;
         13. Patient will receive a dose of any antiplatelet medication (including aspirin) within&#xD;
             14 days before study drug dosing.&#xD;
&#xD;
         14. Patient has malabsorption disorders (e.g., cystic fibrosis or short bowel syndrome).&#xD;
&#xD;
         15. Patient has an estimated glomerular filtration rate (eGFR) &lt; 30 mL/min.&#xD;
&#xD;
         16. Patient is unable or reluctant to cooperate with the study procedures.&#xD;
&#xD;
         17. Patient has hypersensitivity to other Factor Xa inhibitors, or the components of the&#xD;
             dosage form.&#xD;
&#xD;
         18. Patient has participated in a study with an investigational drug or medical device&#xD;
             within 30 days prior to administration of betrixaban.&#xD;
&#xD;
         19. Patient is female and is either pregnant or breastfeeding a child.&#xD;
&#xD;
         20. Patient is sexually active and is not using medically accepted contraceptive method&#xD;
             (if applicable).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACTCA, Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies &amp; Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Tatarstan Republic</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's City Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pirogov Russian National Research Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution</name>
      <address>
        <city>Nizhnii Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Pediatric Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Children Clinical Hospital</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia Regional Children's Clinical Hospital, Department of Anesthesiology and Intensive Care</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Women's and Children's NHS Foundtation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 7, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betrixaban</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 14, 2021</submitted>
    <returned>May 7, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

